Appointment dossier — Small Cell Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Small Cell Carcinoma
- Cisplatin — Review evidence · 1 positive / 1 negative-mixed · PMID 30397561, 18408396
- Etoposide — Review evidence · 1 positive / 2 negative-mixed · PMID 30397561, 40129783, 37485216, 18408396
- Pembrolizumab — Review evidence · 1 positive · PMID 33163917
- Carboplatin — Review evidence · 0 positive / 1 negative-mixed · PMID 40129783, 37485216
- Durvalumab — Review evidence · 0 positive / 1 negative-mixed · PMID 40129783, 37485216
- Nivolumab †Rx — Review evidence · 0 positive / 1 negative-mixed · PMID 37928288
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
- NCT05398094 · Phase 2 — Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (Spain)
- NCT05498428 · Phase 2 — A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (United States)
- NCT05150691 · Phase 1 / Phase 2 — A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (United States)
- NCT06687941 · Phase 1 — A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors (South Korea)
- NCT04322617 · Phase 2 / Phase 3 — Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer (China)
- NCT06561386 · Phase 3 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (United States)
- NCT06855277 · Phase 3 — Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (United States)
- NCT04423211 · Phase 3 — Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (United States)
- NCT06378892 · Phase 2 — A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (Italy)
- NCT07391813 · Phase 1 / Phase 2 — SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer (Serbia)
- NCT07563738 · Phase 1 / Phase 2 — A 2-part Phase 1/2 Open-label Trial on ODM-212 (United States)
- NCT07264647 · Phase 2 — Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) (Italy)
- NCT06749691 · Phase 2 — Liposomal Irinotecan and Apatinib in ES-SCLC (China)
- NCT07292168 · Phase 1 / Phase 2 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 (Russia)
- NCT06901817 · Phase 2 — A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases (China)
- NCT07276789 · Phase 2 — Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer (United States)
- NCT04704505 · Phase 2 — Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (United States)
Most-relevant first: trials that name Small Cell Carcinoma, then broader trials you may still qualify for. 1537 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07341737), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?